Xanodyne
closedIntegrated specialty pharmaceutical company focused on women’s healthcare and pain management.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD541—811m (Dealroom.co estimates Oct 2009.)
Newport United States (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $5.1m | Series B | |
$20.0m | Series C | ||
| N/A | $170m Valuation: $254m | Growth Equity VC | |
$25.0m | Growth Equity VC | ||
$87.5m | Late VC | ||
| Total Funding | AUD475m | ||
Related Content
Recent News about Xanodyne
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Xanodyne
Edit
ACQUISITION by Xanodyne Jul 2005